GI Onc Now Videos
Advertisement
Dr. Leong showcases the highly anticipated results of the TOPGEAR study in patients with resectable G/GEJ adenocarcinoma.
Dr. Wainberg reviews the data on GI malignancies and notes that it is unclear who should receive radiation before surgery.
Dr. Josep Llovet discusses promising data, including higher PFS and OS, in metastatic liver cancer from the LEAP-012 trial.
Dr. Janjigian shares an overview of the DESTINY-Gastric03 study and the history of T-Dxd for gastric and GEJ cancers.
Dr. Grady opines on whether colonoscopy, stool-based, or blood-based tests will be integrated into CRC screening guidelines.
Dr. Grady discusses ECLIPSE for colorectal cancer screening and the findings that led to approval of the Shield test.
Dr. Lieu breaks down his top uses of AI in GI oncology today, as well as their projected applicability in the near future.
Dr. Amit Mahipal discusses a recent study on atezolizumab plus bevacizumab as a first-line treatment for HCC.
Dr. Dan Kaufman discusses recent research on TGF-β and how it is linked to the development of HCC.
Dr. El-Deiry expands on reducing ALDH1 expression in HT29 cells, and the benefits of targeting ERK1/2 and STAT3 activation.
Dr. Wafik El-Deiry of Brown University discusses his study on regorafenib with TAS-102 for colorectal cancer.
Dr. Joel Rubenstein discusses the recent American Gastroenterological Association guideline on EET for Barrett's esophagus.
Dr. Cecchini explains how ctDNA was used in this study as well as which methods were used for analyzing ctDNA levels.
Grace-Ann Fasaye discusses the elevated lifetime risk of gastric cancer in patients with CDH1 gene variants.
Dr. Luo describes the performance of the two-fusion gene + α-fetal protein logistic regression model.
Dr. Luo explains the potential benefits of machine learning for patients with hepatocellular carcinoma.
Dr. Arun Nagarajan explains how disparities in testing can affect survival and treatment outcomes for patients with mCRC.
Drs. Uboha and Karasic discuss the benefits and considerations of treating gastric cancer with an anti-CCR8 antibody.
Dr. Faber highlights the implications of increased expression of PDCD1LG2, PDCD1, and HAVCR2 in USC PDAC tumors.
Drs. David H. Ilson and Nataliya Uboha highlight the final OS results of the phase 3 SPOTLIGHT study.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.